BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10696135)

  • 1. Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: nonrenal excretion of serum methotrexate.
    Shinozaki T; Watanabe H; Tomidokoro R; Yamamoto K; Horiuchi R; Takagishi K
    Med Pediatr Oncol; 2000 Mar; 34(3):226-8. PubMed ID: 10696135
    [No Abstract]   [Full Text] [Related]  

  • 2. Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
    Al-Turkmani MR; Law T; Narla A; Kellogg MD
    Clin Chem; 2010 Dec; 56(12):1792-4. PubMed ID: 21119035
    [No Abstract]   [Full Text] [Related]  

  • 3. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
    Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
    Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Managing methotrexate toxicity: a case report].
    Fernández Megía MJ; Alós Almiñana M; Terol Castera MJ
    Farm Hosp; 2004; 28(5):371-4. PubMed ID: 15504095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
    Widemann BC; Schwartz S; Jayaprakash N; Christensen R; Pui CH; Chauhan N; Daugherty C; King TR; Rush JE; Howard SC
    Pharmacotherapy; 2014 May; 34(5):427-39. PubMed ID: 24132809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
    Tuffaha HW; Al Omar S
    J Oncol Pharm Pract; 2011 Jun; 17(2):136-40. PubMed ID: 19833686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary.
    Milone MC
    Clin Chem; 2010 Dec; 56(12):1795-6. PubMed ID: 21119036
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
    Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary.
    Fox E; Balis FM
    Clin Chem; 2010 Dec; 56(12):1795. PubMed ID: 21119037
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of charcoal hemoperfusion for removal of plasma methotrexate in a patient with acute renal failure.
    Nemoto T; Imai C; Kaneko U; Takachi T; Iwabuchi H; Tanaka A; Nakamura G; Ogose A; Uchiyama M
    Pediatr Hematol Oncol; 2009; 26(7):520-5. PubMed ID: 19863208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate in fibroblastic osteosarcoma.
    Chowbay B; Siong KK
    Ann Pharmacother; 2001 Dec; 35(12):1669. PubMed ID: 11793640
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
    Wippel B; Gundle KR; Dang T; Paxton J; Bubalo J; Stork L; Fu R; Ryan CW; Davis LE
    Cancer Med; 2019 Jan; 8(1):111-116. PubMed ID: 30580500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective removal of methotrexate by high-flux hemodialysis.
    Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
    Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
    Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
    J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
    Young EP; Cheng WS; Bernhardt MB; Wang LL; Rainusso N; Foster JH
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28123. PubMed ID: 31867853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of anion-exchange resins in the treatment of antibiotic-associated pseudomembranous colitis.
    Ariano RE; Zhanel GG; Harding GK
    CMAJ; 1990 May; 142(10):1049-51. PubMed ID: 2186849
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma.
    Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between methotrexate and ciprofloxacin.
    Dalle JH; Auvrignon A; Vassal G; Leverger G
    J Pediatr Hematol Oncol; 2002 May; 24(4):321-2. PubMed ID: 11972105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs.
    Bacci G; Ferrari S; Picci P; Zolezzi C; Gherlinzoni F; Iantorno D; Cazzola A
    J Chemother; 1996 Dec; 8(6):472-8. PubMed ID: 8981189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.